dlee38, very much appreciated and enjoyed your feedback on this topic.

On another matter, I questioned the following (as noted below) a few posts ago but did not get a response. This was not directed to you specifically. So as I believe you are in the medical field, I would appreciate and welcome your comments, if you would, please. 

"Is it possible that the COVID-19 Trial design is a bit much and too complicated to simply know if Apabetalone avoids the intensive care unit altogether? And according to the trial, Apabetalone is to be administered BID with meals. Do they serve meals in the ICU? And does the standard of care administered to patients include monoclonal antibody treatment such as Remdesivir?

It would be nice to get feedback from the scientists on this Hub in this regard."

https://clinicaltrials.gov/ct2/show/NCT04894266

Koo